Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
Pharmacogenomics|January 19, 2013
Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicityBrian C Jensen, Howard L McLeod
Advanced Drug Delivery Reviews|June 20, 2024
Navigating cancer therapy induced cardiotoxicity: From pathophysiology to treatment innovationsJessica Tetterton-Kellner, Brian C Jensen, Juliane Nguyen
American Journal of Physiology. Heart and Circulatory Physiology|December 4, 2020
Cardiac α1A-adrenergic receptors: emerging protective roles in cardiovascular diseasesJiandong Zhang, Paul C Simpson, Brian C Jensen
Biorxiv : the Preprint Server for Biology|February 23, 2026
Phosphatidylserine-Based Liposomes Encapsulating DMX-5804 Protect Against Doxorubicin-Induced CardiotoxicityJessica Tetterton-Kellner, Brian C Jensen, Juliane Nguyen
Naunyn-Schmiedeberg'S Archives of Pharmacology|November 8, 2008
Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecificBrian C Jensen, Philip M Swigart, Paul C Simpson
Frontiers in Cardiovascular Medicine|February 3, 2022
Novel Mechanisms of Anthracycline-Induced Cardiovascular Toxicity: A Focus on Thrombosis, Cardiac Atrophy, and Programmed Cell DeathSilvio Antoniak, Sukanya Phungphong, Zhaokang Cheng, et al.
Cardiovascular Toxicology|September 2, 2017
Cardiovascular Effects of the MEK Inhibitor, Trametinib: A Case Report, Literature Review, and Consideration of MechanismMary Banks, Karen Crowell, Amber Proctor, et al.
Journal of Cardiovascular Pharmacology|October 23, 2013
Alpha-1-adrenergic receptors in heart failure: the adaptive arm of the cardiac response to chronic catecholamine stimulationBrian C Jensen, Timothy D OʼConnell, Paul C Simpson
Journal of Molecular and Cellular Cardiology|December 2, 2010
Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failureBrian C Jensen, Timothy D O'Connell, Paul C Simpson
Pageof 9